Multi-center phase 2 trial finds spread of nasopharyngeal carcinoma is reduced by bevacizumab:
NCI Cancer Center News
Combining the widely used anti-cancer drug bevacizumab with standard chemoradiation therapy is safe and could prolong survival in patients with advanced nasopharyngeal carcinoma, according to a new phase 2 trial published Online First in today’s The Lancet Oncology. The results indicate that bevacizumab might be more effective at preventing the spread of nasopharyngeal carcinoma to other parts of the body, the most common cause of death in patients with advanced disease.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.